109 Results for "

VEGF-A

" in MedChemExpress (MCE) Product Catalog:
Products (109)

109 Results for "VEGF-A" in MCE Product Catalog:

  • Recombinant Proteins Recommended:
62
62 Publications Verification
Cat. No.: HY-P9906
CAS No.: 216974-75-3
Synonyms: Anti-Human VEGF, Humanized Antibody

Target:  

VEGFR

Research Areas:  

Cancer

Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
loading...
    loading...
62
62 Publications Verification
Cat. No.: HY-P9906A
CAS No.: 216974-75-3

Target:  

VEGFR

Research Areas:  

Cancer

Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity .
loading...
    loading...
34
34 Cited Publications
Cat. No.: HY-B1788
CAS No.: 81-24-3
Synonyms: N-Choloyltaurine
Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .
loading...
    loading...
34
34 Cited Publications
Cat. No.: HY-N0545
CAS No.: 145-42-6
Synonyms: Sodium taurocholate; N-Choloyltaurine sodium
Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .
loading...
    loading...
34
34 Cited Publications
Cat. No.: HY-B1131
CAS No.: 345909-26-4
Synonyms: Sodium taurocholate hydrate; N-Choloyltaurine sodium salt hydrate
Taurocholic acid (N-Choloyltaurine) sodium salt hydrate has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium salt hydrate has immunoregulation effect .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-P7110A
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: VEGFA; Vascular Endothelial Growth Factor A; VEGF; VPF; Vascular Permeability Factor; Vascular Endothelial Growth Factor A, Long Form; VEGF-A; L-VEGF; Vascular Endothelial Growth Factor A121; Vascular Endothelial Growth Factor A165; Vascular Endothelial G
Species:  
Source:  
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-117661
CAS No.: 1818389-84-2
Target:  

SRPK VEGFR

Research Areas:  

Cardiovascular Disease Cancer

SPHINX31 is a potent and selective SRPK1 inhibitor, with an IC50 of 5.9 nM. SPHINX31 inhibits phosphorylation of serine/arginine-rich splicing factor 1 (SRSF1). SPHINX31 also decreases the mRNA expression of pro-angiogenic VEGF-A165a isoform. SPHINX31 can be used to research neovascular eye disease .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-10799
CAS No.: 1210945-69-9
Purity:  98.03%
Target:  

Complement System

Research Areas:  

Cancer

EG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with an IC50 of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2 .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-P7312
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: VEGFA; Vascular Endothelial Growth Factor A; VEGF; VPF; Vascular Permeability Factor; Vascular Endothelial Growth Factor A, Long Form; VEGF-A; L-VEGF; Vascular Endothelial Growth Factor A121; Vascular Endothelial Growth Factor A165; Vascular Endothelial G
Species:  
Source:  
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-P80929
Synonyms: VEGFA; VEGF; Vascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF

Host:  

Rabbit

Application:  

WB

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-124593
CAS No.: 1256565-36-2
Purity:  99.89%
Synonyms: Emvododstat
PTC299 is an orally active inhibitor of VEGFA mRNA translation that selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of dihydroorotate dehydrogenase (DHODH). PTC299 shows good oral bioavailability and lack of off-target kinase inhibition and myelosuppression. PTC299 can be useful for the research of hematologic malignancies .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-N2187
CAS No.: 43043-74-9
Deoxyshikonin increases the expression of VEGF-C and VEGF-A mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction and binds to specific DNA sequences targeted by HIF. Deoxyshikonin inhibited colorectal cancer (CRC) through the PI3K/Akt/mTOR pathway. Deoxyshikonin has proangiogenesis effect and antitumor activity. Deoxyshikonin is an antibacterial agent against methicillin-resistant S. aureus (MRSA) and S. pneumonia (MIC=17 μg/mL) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P7311
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: VEGFA; Vascular Endothelial Growth Factor A; VEGF; VPF; Vascular Permeability Factor; Vascular Endothelial Growth Factor A, Long Form; VEGF-A; L-VEGF; Vascular Endothelial Growth Factor A121; Vascular Endothelial Growth Factor A165; Vascular Endothelial G
Species:  
Rat
Source:  
CHO
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N7043
CAS No.: 142796-21-2
Isosilybin A is a PPARγ agonist that can be isolated from silymarin. Isosilybin A activates extrinsic and intrinsic pathways of apoptosis through targeting of the Akt-NF-kB-AR axis. Isosilybin A can relieve the inflammatory response in the rosacea model via inhibiting Erk and p38 signaling pathways and M1 macrophage polarization, with its targets related to RELA and VEGFA. Isosilybin A has anti-prostate cancer (PCA) activity [1][2][3].
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P7420
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: VEGFA; Vascular Endothelial Growth Factor A; VEGF; VPF; Vascular Permeability Factor; Vascular Endothelial Growth Factor A, Long Form; VEGF-A; L-VEGF; Vascular Endothelial Growth Factor A121; Vascular Endothelial Growth Factor A165; Vascular Endothelial G
Species:  
Source:  
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P70458A
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: VEGFA; Vascular Endothelial Growth Factor A; VEGF; VPF; Vascular Permeability Factor; Vascular Endothelial Growth Factor A, Long Form; VEGF-A; L-VEGF; Vascular Endothelial Growth Factor A121; Vascular Endothelial Growth Factor A165; Vascular Endothelial G
Species:  
Source:  
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99675
CAS No.: 2428381-53-5
Synonyms: AK112

Target:  

PD-1/PD-L1 VEGFR

Research Areas:  

Cancer

Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P990148

Target:  

VEGFR

Research Areas:  

Cancer

Anti-Mouse VEGF-A Antibody (2G11-2A05) is a rat-derived IgG2a κ type antibody inhibitor, tragrting to mouse VEGF-A with high affinity. Anti-Mouse VEGF-A Antibody (2G11-2A05) shows good anti-tumor effect in gastric cancer xenograft models .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P9951A
CAS No.: 347396-82-1
Synonyms: RG-6321 (anti-VEGF)

Target:  

VEGFR

Research Areas:  

Cardiovascular Disease

Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P9920A
CAS No.: 947687-13-0

Target:  

VEGFR

Research Areas:  

Cancer

Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .
loading...
    loading...